Clinical Trials Logo

Clinical Trial Summary

The study will include data from a nationwide Danish cohort of postmenopausal women and the United States of America (US) cohort of postmenopausal women. The Danish nationwide cohort will be established through linkage of Danish national patient registries. The US cohort will be established based on data from US claims database, Truven. The aim of this study is to evaluate whether exposure to Vagifem® increases the rate of endometrial cancer in postmenopausal women.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05243823
Study type Observational
Source Novo Nordisk A/S
Contact
Status Completed
Phase
Start date January 15, 2022
Completion date July 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT01085877 - Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis Phase 1
Completed NCT00108849 - Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms Phase 3
Completed NCT00464971 - Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial Phase 3
Completed NCT00431132 - Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis Phase 3
Completed NCT01486979 - Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis Phase 1
Completed NCT00465192 - Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis Phase 3
Completed NCT01507454 - Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency N/A